Brokerages Set Insulet Co. (NASDAQ:PODD) PT at $306.53

Shares of Insulet Co. (NASDAQ:PODD) have been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $306.53.

A number of research firms recently weighed in on PODD. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada initiated coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price for the company. Barclays increased their price target on shares of Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Finally, Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 target price on the stock in a research report on Tuesday, May 13th.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares of the company’s stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after buying an additional 178,976 shares during the period. Baillie Gifford & Co. raised its holdings in Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after acquiring an additional 79,982 shares during the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock valued at $463,347,000 after acquiring an additional 40,566 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Finally, Groupama Asset Managment boosted its holdings in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after purchasing an additional 3,759 shares during the last quarter.

Insulet Stock Performance

NASDAQ PODD opened at $327.47 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a 52-week low of $170.67 and a 52-week high of $329.00. The business’s 50-day moving average price is $267.35 and its 200 day moving average price is $267.99. The firm has a market cap of $23.05 billion, a P/E ratio of 56.56, a P/E/G ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $543.20 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. On average, equities research analysts expect that Insulet will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.